开发了在K 2 S 2 O 8作为易于处理的氧化剂存在下,使用氯化钠/溴化物/碘化物作为卤素源,方便地卤化2-芳基咪唑并[1,2- a ]吡啶的方法。本工作提供了一种快速有效地获得3-氯-,3-溴-和3-碘-2-芳基咪唑并[1,2- a ]吡啶的方法,这些吡啶基很容易转化为C 3取代的咪唑并[1,2] -一个]吡啶通过交叉偶联反应。
Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor
作者:Matthew D. Vera、Joseph T. Lundquist、Murty V. Chengalvala、Joshua E. Cottom、Irene B. Feingold、Lloyd M. Garrick、Daniel M. Green、Diane B. Hauze、Charles W. Mann、John F. Mehlmann、John F. Rogers、Linda Shanno、Jay E. Wrobel、Jeffrey C. Pelletier
DOI:10.1016/j.bmcl.2010.02.099
日期:2010.4
orally active GnRH antagonists based on a 4-piperazinylbenzimidazole template, we sought to investigate the properties of heterocyclic isosteres of the benzimidazole template. We report here the synthesis and biological activity of eight novel scaffolds, including imidazopyridines, benzothiazoles and benzoxazoles. The 2-(4-tert-butylphenyl)-8-(piperazin-1-yl)imidazo[1,2-a]pyridine ring system was shown
K2S2O8-Mediated halogenation of 2-arylimidazo[1,2-a]pyridines using sodium halides as the halogen sources
作者:Praewpan Katrun、Chutima Kuhakarn
DOI:10.1016/j.tetlet.2019.03.008
日期:2019.4
halogenation of 2-arylimidazo[1,2-a]pyridines using sodium chloride/bromide/iodide as the halogen sources in the presence of K2S2O8 as an easy-to-handle oxidizing agent was developed. The present work offers an efficient and rapid access to 3-chloro-, 3-bromo- and 3-iodo-2-arylimidazo[1,2-a]pyridines which can be readily converted to C3-substituted imidazo[1,2-a]pyridines by cross-coupling reactions.
开发了在K 2 S 2 O 8作为易于处理的氧化剂存在下,使用氯化钠/溴化物/碘化物作为卤素源,方便地卤化2-芳基咪唑并[1,2- a ]吡啶的方法。本工作提供了一种快速有效地获得3-氯-,3-溴-和3-碘-2-芳基咪唑并[1,2- a ]吡啶的方法,这些吡啶基很容易转化为C 3取代的咪唑并[1,2] -一个]吡啶通过交叉偶联反应。
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor
申请人:Lundquist Theodore Joseph
公开号:US20060270848A1
公开(公告)日:2006-11-30
The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.